1. Home
  2. BGB vs STTK Comparison

BGB vs STTK Comparison

Compare BGB & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Strategic Credit 2027 Term Fund of Beneficial Interest

BGB

Blackstone Strategic Credit 2027 Term Fund of Beneficial Interest

HOLD

Current Price

$11.32

Market Cap

506.7M

Sector

Finance

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$6.90

Market Cap

538.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGB
STTK
Founded
2012
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
506.7M
538.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BGB
STTK
Price
$11.32
$6.90
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$10.00
AVG Volume (30 Days)
120.6K
1.8M
Earning Date
01-01-0001
05-01-2026
Dividend Yield
9.75%
N/A
EPS Growth
N/A
53.02
EPS
N/A
N/A
Revenue
N/A
$1,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.85
$0.71
52 Week High
$12.65
$8.33

Technical Indicators

Market Signals
Indicator
BGB
STTK
Relative Strength Index (RSI) 52.06 65.14
Support Level $11.29 $5.81
Resistance Level $11.36 $7.68
Average True Range (ATR) 0.05 0.59
MACD 0.00 0.29
Stochastic Oscillator 63.64 88.54

Price Performance

Historical Comparison
BGB
STTK

About BGB Blackstone Strategic Credit 2027 Term Fund of Beneficial Interest

Blackstone Strategic Credit Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income. The secondary objective of the fund is to seek the preservation of capital. Under normal market conditions, the Fund invests at least 80% of its Managed Assets in senior, secured floating-rate loans. The fund also invest in second-lien loans and high yield bonds and employs financial leverage, which may increase risk to the Fund. The Fund has a limited term and absent shareholder approval to extend the life of the Fund.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: